Thermo Fisher Scientific Human SPG11 Synthetic Peptide

Applications

Control (Ctrl)

• Assay-dependent

Blocking Assay (BLOCK)

• Assay-dependent

Product Specifications

Product Specific Information

This peptide corresponds to 15 amino acids near the carboxy terminus of human SPG11.
PEP-0799 can be used as a blocking peptide with polyclonal antibody PA5-20683.

Target Information

Hereditary spastic paraplegias (HSPs) are genetically and phenotypically heterogeneous disorders.
Spastic paraplegia with thinning of the corpus callosum (ARHSP-TCC) is a relatively frequent form of complicated hereditary spastic paraplegia (cHSP) characterized by mental retardation and muscle stiffness at onset, followed by slowly progressive paraparesis and cognitive deterioration.
Mutations of the SPG11 gene encoding the spatacsin protein have been identified as a major cause of HSP-TCC. Spatacsin is a potential transmembrane protein phosphorylated upon DNA damage and expressed throughout the brain, with high expression in the cerebellum.
SPG11 mutations may be more frequent in familial than sporadic forms of cHSP without TCC. Kjellin syndrome is associated with mutations in both SPG15 and SPG11 genes.
Recent studies indicate that Parkinsonism may initiate SPG11-linked HSP TCC and that SPG11 may cause juvenile Parkinsonism.

For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.